ClinicalTrials.gg
TerminatedNCT00484718Updated Apr 14, 2021Results posted

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

A Phase 4 interventional study of celecoxib and Oxycodone in Osteoarthritis, sponsored by Pfizer. Terminated at 2 sites in United States. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-04-14.

Sponsored by Pfizer · Phase 4, Interventional, and Other

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing celecoxib in Osteoarthritis — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis.

Enrollment
14th of 14
6 · median 150
Started
2008
the only one that year
Phase 4
10 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
1 of 14
Pfizer

Among the 14 studies testing celecoxib in Osteoarthritis, this one is the 14th largest by enrollment, is the only one that started in 2008, is one of 10 in phase 4, and was the 9th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, or all of them as a file.
02

Study summary

The Purpose of this trial is to evaluate the use of a cross-over trial design in an osteoarthritis population. We will determine the inter- and intra-subject variability in osteoarthritis (OA) endpoints and evaluate if efficacy can be detected by measuring OA endpoints following treatment with 2 different types of analgesics in a crossover study of this design.

Read the detailed description

Methodology study to evaluate the use of a cross over design and gait analysis. The study was terminated by mutual consent with the study site at a meeting on the 1 April 2009, because of slow recruitment due to a high screen fail rate. The study was not stopped for safety reasons.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has been taking an NSAID at least 15 of the past 30 days for index knee pain
  • Grades 2 or 3 OA as defined by the Kellgren and Lawrence Grading System of the medial tibiofemoral joint (joint space narrowing in the medial compartment > lateral compartment as assessed by x-ray) using the Altman Atlas of OA7. This must be documented with a report from an x-ray of the study joint taken either at screening or within 1 year prior to screening
  • Subject meets American College of Rheumatology (ACR) clinical classification criteria for osteoarthritis of the knee, defined by the following: Knee pain and at least 3 of the following: oAge >50 oMorning stiffness \<30 minutes oCrepitus on active motion oBony tenderness oBony enlargement oNo palpable warmth of synovium.

Exclusion criteria

Exclusion Criteria:

  • Subject has a documented history of an allergic reaction (hives, rash, etc.) or a intolerance to celecoxib, sulfonamides, aspirin, or opioids including oxycodone
  • Significant pain outside the index knee, including significant hip or back pain that can not be distinguished from OA pain or that interferes with ability to walk. (Patients with bilateral knee OA will be allowed into the study. The index knee should be defined as the more painful knee
  • Predominantly patellofemoral knee osteoarthritis in the index knee as assessed by clinical examination
  • Subject who are unable to discontinue all formulations of prior analgesics other than acetaminophen during the of the study, or who are anticipated to be unable to discontinue rescue medication for 24 hours prior to the respective visits. (Low dose aspirin may be taken for cardiac prophylaxis
  • Excessive signal knee joint laxity indicative of functional ligamentous deficiency
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
6 participants (actual)

Study arms

  • Active comparator
    A

    Drug: celecoxib

  • Active comparator
    B

    Drug: Oxycodone

  • Placebo comparator
    C

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Knee Pain Intensity Measured by Numeric Rating Scale (NRS) at Week 12

    The severity of arthritis pain in participant's signal knee at the time of the visit was assessed using an 11-point NRS, ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Knee Pain Intensity Measured by Visual Analog Scale (VAS) at Week 12

    The severity of arthritis pain in participant's signal knee was assessed using a 100-millimeter (mm) VAS ranging from 0 mm = no pain and 100 mm = most severe pain. Higher score indicate more pain.

    Time frame: Baseline, Week 12

  3. Change From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Pain Subscale Score at Week 12

    WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). The index consists of 24 questions (5 pain, 2 stiffness, and 17 physical function). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of to be replaced/replaced index joint (knee or hip) during past 48 hours. The WOMAC pain subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse pain. Pain subscale total score ranges from 0 to 20, with higher scores indicating worse pain.

    Time frame: Baseline, Week 12

  4. Change From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Physical Function Subscale Score at Week 12

    WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in in the study joint during past 48 hours. The WOMAC physical function subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse physical function. Physical function subscale scores range from 0 to 68, where higher scores indicated more difficulty in performing daily activities.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Stiffness Subscale Score at Week 12

    WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). Stiffness was defined as a sensation of decreased ease of movement in study joint. The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the in the study joint during the past 48 hours. The WOMAC stiffness subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse stiffness. The stiffness subscale score ranges from 0 to 8, where higher scores indicated worse stiffness.

    Time frame: Baseline, Week 12

  6. Change From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Total Score at Week 12

    WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). The WOMAC composite index was the sum of 24 individual questions regarding subscales of pain, stiffness and physical function (for each item score range: 0 \[minimum\] to 4 \[maximum\], higher score indicating worse study joint condition). Total score was sum of the 3 subscale scores, giving a possible overall score range of 0 (minimum) to 96 (maximum). Higher score indicating the worse level of pain, stiffness and physical function.

    Time frame: Baseline, Week 12

  7. Change From Baseline in Knee Adduction Moment at Week 12

    Adduction (external) moment was defined as the ground-generated torque that forces the distal tibia toward the midline of the body, which forces the knee away from the midline, into a varus or "bow-legged" position. External knee adduction moment was assessed as percent body weight\*height (%BW\*ht).

    Time frame: Baseline, Week 12

  8. Change From Baseline in Quadriceps Inhibition at Week 12

    Quadriceps inhibition was assessed in terms of flexion-extension range of motion and normalized mid stance knee flexion angle in degrees.

    Time frame: Baseline, Week 12

  9. Change From Baseline in Peak Ground Reaction Force at Week 12

    Change from baseline in peak ground reaction force in body weight\*seconds (BW\*sec) was assessed with the help of a multicomponent force plate.

    Time frame: Baseline, Week 12

  10. Change From Baseline in Total Ground Reaction Force at Week 12

    Change from baseline in total ground reaction force in body weight\*seconds was assessed with the help of a multicomponent force plate.

    Time frame: Baseline, Week 12

  11. Change From Baseline in Stride Length at Week 12

    The level walking was assessed by stride length; assessment was done based on 6 stride cycles over a range of walking speeds.

    Time frame: Baseline, Week 12

  12. Change From Baseline in Walking Speed at Week 12

    Change from baseline in walking speed in meters per second was assessed.

    Time frame: Baseline, Week 12

  13. Change From Baseline in Cadence at Week 12

    Cadence was defined as the rate at which a person walk, expressed in steps per minute.

    Time frame: Baseline, Week 12

  14. Change From Baseline in Patient Global Assessment of Arthritic Condition (PGAAC) Score at Week 12

    The PGAAC is self-administered measure in which participants answered the following question: "considering all the ways the OA in your signal knee affects you, how are you doing today?". Participants rated their condition using the following scale: 1= very good (no symptoms and no limitation of normal activities); 2= good (mild symptoms and no limitation of normal activities); 3= fair (moderate symptoms and limitation of some normal activities); 4= poor (severe symptoms and inability to carry out most normal activities); 5= very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.

    Time frame: Baseline, Week 12

07

Results

Posted Apr 14, 2021
Limitations and caveats
No efficacy analysis were conducted, as this study was stopped due to a high screen failure rate before the planned enrollment required to carry out the pre-specified efficacy analysis.

Participant flow

Treatment Period 1 (2 Weeks)
Participant flow — Treatment Period 1 (2 Weeks)
MilestonePlacebo Then Celecoxib Then OxycodonePlacebo Then Oxycodone Then CelecoxibCelecoxib Then Placebo Then OxycodoneCelecoxib Then Oxycodone Then PlaceboOxycodone Then Placebo Then CelecoxibOxycodone Then Celecoxib Then Placebo
Started111111
Completed111111
Not completed000000
Washout Period (2 Weeks)
Participant flow — Washout Period (2 Weeks)
MilestonePlacebo Then Celecoxib Then OxycodonePlacebo Then Oxycodone Then CelecoxibCelecoxib Then Placebo Then OxycodoneCelecoxib Then Oxycodone Then PlaceboOxycodone Then Placebo Then CelecoxibOxycodone Then Celecoxib Then Placebo
Started111111
Completed111111
Not completed000000
Treatment Period 2 (2 Weeks)
Participant flow — Treatment Period 2 (2 Weeks)
MilestonePlacebo Then Celecoxib Then OxycodonePlacebo Then Oxycodone Then CelecoxibCelecoxib Then Placebo Then OxycodoneCelecoxib Then Oxycodone Then PlaceboOxycodone Then Placebo Then CelecoxibOxycodone Then Celecoxib Then Placebo
Started111111
Completed111111
Not completed000000
Washout Period (2 Weeks)
Participant flow — Washout Period (2 Weeks)
MilestonePlacebo Then Celecoxib Then OxycodonePlacebo Then Oxycodone Then CelecoxibCelecoxib Then Placebo Then OxycodoneCelecoxib Then Oxycodone Then PlaceboOxycodone Then Placebo Then CelecoxibOxycodone Then Celecoxib Then Placebo
Started111111
Completed111111
Not completed000000
Treatment Period 3 (2 Weeks)
Participant flow — Treatment Period 3 (2 Weeks)
MilestonePlacebo Then Celecoxib Then OxycodonePlacebo Then Oxycodone Then CelecoxibCelecoxib Then Placebo Then OxycodoneCelecoxib Then Oxycodone Then PlaceboOxycodone Then Placebo Then CelecoxibOxycodone Then Celecoxib Then Placebo
Started111111
Completed111111
Not completed000000

Outcome measures

PrimaryChange From Baseline in Knee Pain Intensity Measured by Numeric Rating Scale (NRS) at Week 12

The severity of arthritis pain in participant's signal knee at the time of the visit was assessed using an 11-point NRS, ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Knee Pain Intensity Measured by Visual Analog Scale (VAS) at Week 12

The severity of arthritis pain in participant's signal knee was assessed using a 100-millimeter (mm) VAS ranging from 0 mm = no pain and 100 mm = most severe pain. Higher score indicate more pain.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Pain Subscale Score at Week 12

WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). The index consists of 24 questions (5 pain, 2 stiffness, and 17 physical function). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of to be replaced/replaced index joint (knee or hip) during past 48 hours. The WOMAC pain subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse pain. Pain subscale total score ranges from 0 to 20, with higher scores indicating worse pain.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Physical Function Subscale Score at Week 12

WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in in the study joint during past 48 hours. The WOMAC physical function subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse physical function. Physical function subscale scores range from 0 to 68, where higher scores indicated more difficulty in performing daily activities.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Stiffness Subscale Score at Week 12

WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). Stiffness was defined as a sensation of decreased ease of movement in study joint. The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the in the study joint during the past 48 hours. The WOMAC stiffness subscale score for each question ranges from 0 (minimum) to 4 (maximum), higher scores signifies worse stiffness. The stiffness subscale score ranges from 0 to 8, where higher scores indicated worse stiffness.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Western Ontario and McMaster (WOMAC) Osteoarthritis Index Total Score at Week 12

WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA of the hip and/or knee). The WOMAC composite index was the sum of 24 individual questions regarding subscales of pain, stiffness and physical function (for each item score range: 0 \[minimum\] to 4 \[maximum\], higher score indicating worse study joint condition). Total score was sum of the 3 subscale scores, giving a possible overall score range of 0 (minimum) to 96 (maximum). Higher score indicating the worse level of pain, stiffness and physical function.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Knee Adduction Moment at Week 12

Adduction (external) moment was defined as the ground-generated torque that forces the distal tibia toward the midline of the body, which forces the knee away from the midline, into a varus or "bow-legged" position. External knee adduction moment was assessed as percent body weight\*height (%BW\*ht).

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Quadriceps Inhibition at Week 12

Quadriceps inhibition was assessed in terms of flexion-extension range of motion and normalized mid stance knee flexion angle in degrees.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Peak Ground Reaction Force at Week 12

Change from baseline in peak ground reaction force in body weight\*seconds (BW\*sec) was assessed with the help of a multicomponent force plate.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Total Ground Reaction Force at Week 12

Change from baseline in total ground reaction force in body weight\*seconds was assessed with the help of a multicomponent force plate.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Stride Length at Week 12

The level walking was assessed by stride length; assessment was done based on 6 stride cycles over a range of walking speeds.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Walking Speed at Week 12

Change from baseline in walking speed in meters per second was assessed.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Cadence at Week 12

Cadence was defined as the rate at which a person walk, expressed in steps per minute.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

PrimaryChange From Baseline in Patient Global Assessment of Arthritic Condition (PGAAC) Score at Week 12

The PGAAC is self-administered measure in which participants answered the following question: "considering all the ways the OA in your signal knee affects you, how are you doing today?". Participants rated their condition using the following scale: 1= very good (no symptoms and no limitation of normal activities); 2= good (mild symptoms and no limitation of normal activities); 3= fair (moderate symptoms and limitation of some normal activities); 4= poor (severe symptoms and inability to carry out most normal activities); 5= very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated severe condition.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

Adverse events

Collected over From signing of informed consent to 28 days after the last study drug administration (up to 17 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/6 (0%)5/6 (83.3%)
Celecoxib 100 mg—0/6 (0%)4/6 (66.7%)
Oxycodone 20 mg—0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboCelecoxib 100 mgOxycodone 20 mg
ConstipationGastrointestinal disorders0/60/63/6
NauseaGastrointestinal disorders1/62/63/6
SomnolenceNervous system disorders1/60/63/6
DiarrhoeaGastrointestinal disorders1/60/62/6
HeadacheNervous system disorders0/61/62/6
Vision blurredEye disorders1/60/60/6
DyspepsiaGastrointestinal disorders0/61/61/6
FlatulenceGastrointestinal disorders0/61/61/6
ChillsGeneral disorders0/60/61/6
DizzinessNervous system disorders1/61/61/6

Baseline characteristics

Baseline analysis population included all randomized participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(Years)All Participants
Mean62.5 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female2
Male4
08

Study locations

2 sites
  • VAPAHCS
    Palo Alto, California 94304-1290, United States
  • Stanford University
    Stanford, California 94305, United States
09

References and documents

Publications

  • Asay JL, Boyer KA, Andriacchi TP. Repeatability of gait analysis for measuring knee osteoarthritis pain in patients with severe chronic pain. J Orthop Res. 2013 Jul;31(7):1007-12. doi: 10.1002/jor.22228. Epub 2013 Mar 18. PubMed 23508626 ↗
  • Boyer KA, Angst MS, Asay J, Giori NJ, Andriacchi TP. Sensitivity of gait parameters to the effects of anti-inflammatory and opioid treatments in knee osteoarthritis patients. J Orthop Res. 2012 Jul;30(7):1118-24. doi: 10.1002/jor.22037. Epub 2011 Dec 16. PubMed 22179861 ↗

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2008 to primary completion in Jun 2009, 16 months.

Results were first posted in Apr 2021, 11 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2007
First posted
Jun 11, 2007
StartActual
Jan 17, 2008
Primary completionActual
Jun 10, 2009
CompletionActual
Jun 10, 2009
Results first posted
Apr 14, 2021
Last update
Apr 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00484718
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 11, 2007
Start date
Jan 17, 2008
Primary completion
Jun 10, 2009
Completion
Jun 10, 2009
Results posted
Apr 14, 2021
Last update
Apr 14, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Celecoxib · Oxycodone

Start the discussion